Inogen, Inc (NASDAQ:INGN) – Research analysts at Leerink Swann raised their Q1 2018 EPS estimates for shares of Inogen in a research note issued to investors on Tuesday. Leerink Swann analyst D. Antalffy now anticipates that the medical technology company will post earnings per share of $0.31 for the quarter, up from their prior estimate of $0.19. Leerink Swann has a “Outperform” rating and a $120.00 price objective on the stock. Leerink Swann also issued estimates for Inogen’s FY2018 earnings at $1.47 EPS and FY2019 earnings at $1.44 EPS.

A number of other analysts have also recently commented on INGN. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 price objective for the company in a research report on Thursday. Needham & Company LLC increased their target price on Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a report on Wednesday. BidaskClub cut Inogen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Finally, Piper Jaffray Companies reiterated a “hold” rating and set a $90.00 target price on shares of Inogen in a report on Tuesday, September 12th. Three analysts have rated the stock with a hold rating, three have given a buy rating and two have given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $103.14.

ILLEGAL ACTIVITY NOTICE: “Q1 2018 EPS Estimates for Inogen, Inc (INGN) Lifted by Leerink Swann” was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/12/q1-2018-eps-estimates-for-inogen-inc-ingn-lifted-by-leerink-swann.html.

Shares of Inogen (NASDAQ:INGN) opened at $114.19 on Friday. Inogen has a 1 year low of $59.84 and a 1 year high of $124.90. The company has a market cap of $2,383.15, a price-to-earnings ratio of 92.84, a P/E/G ratio of 4.80 and a beta of 0.99.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.29 by $0.04. Inogen had a return on equity of 13.37% and a net margin of 11.36%. The company had revenue of $69.00 million for the quarter, compared to the consensus estimate of $63.55 million. During the same quarter in the prior year, the business posted $0.25 EPS. The firm’s quarterly revenue was up 26.8% on a year-over-year basis.

A number of hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN lifted its position in Inogen by 15.7% during the third quarter. Wells Fargo & Company MN now owns 300,025 shares of the medical technology company’s stock worth $28,533,000 after acquiring an additional 40,798 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Inogen by 12.0% during the third quarter. Legal & General Group Plc now owns 33,188 shares of the medical technology company’s stock worth $3,155,000 after purchasing an additional 3,559 shares during the period. Amundi Pioneer Asset Management Inc. bought a new position in shares of Inogen during the third quarter worth approximately $3,646,000. American International Group Inc. increased its holdings in shares of Inogen by 6.6% during the third quarter. American International Group Inc. now owns 13,480 shares of the medical technology company’s stock worth $1,282,000 after purchasing an additional 829 shares during the period. Finally, Yorktown Management & Research Co Inc bought a new position in shares of Inogen during the third quarter worth approximately $385,000.

In related news, Director Raymond Huggenberger sold 14,000 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $91.67, for a total value of $1,283,380.00. Following the completion of the sale, the director now directly owns 7,808 shares in the company, valued at approximately $715,759.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Matt Scribner sold 2,500 shares of the firm’s stock in a transaction dated Friday, August 18th. The shares were sold at an average price of $92.45, for a total transaction of $231,125.00. Following the completion of the sale, the executive vice president now owns 6,964 shares of the company’s stock, valued at $643,821.80. The disclosure for this sale can be found here. Insiders sold a total of 67,000 shares of company stock valued at $6,424,010 over the last quarter. 5.31% of the stock is currently owned by company insiders.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.